产品说明书
Lenumlostat
 |
同义名 : | Pat-1251;GB2064 |
| CAS号 : | 2007885-39-2 | |
| 货号 : | A409897 | |
| 分子式 : | C18H17F4N3O3 | |
| 纯度 : | 98%+ | |
| 分子量 : | 399.339 | |
| MDL号 : | MFCD31657357 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 125 mg/mL(313.02 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 100 mg/mL(250.41 mM) |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | PAT-1251 is a potent, selective and oral Lysyl Oxidase-Like 2 (LOXL2) inhibitor, with IC50s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC50s, 0.10, 0.12, and 0.16 μM, respectively); PAT-1251 has entered clinical development with the potential to treat a number of fibrotic diseases. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02852551 | Healthy | Phase 1 | Completed | - | United Kingdom ... 展开 >> Covance Clinical Research Unit Ltd. Leeds, United Kingdom, LS2 9LH 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.50mL 0.50mL 0.25mL |
12.52mL 2.50mL 1.25mL |
25.04mL 5.01mL 2.50mL |
